A small phase 3 trial of Leronlimab in critically ill Covid 19 patients

Status: Suspended

Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Mar 2022 According to an CytoDyn media release, Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting
30 Mar 2022 Status changed from recruiting to suspended, according to an CytoDyn media release.
08 Dec 2021 According to a CytoDyn media release, CytoDyn will submit the revised protocol for CD16 providing for a reduction in total enrollment from 330 to 126 patients, with interim efficacy analysis by DSMB after 40% of patients (51 patients) are enrolled and have completed follow-up to Day 28 (potentially in 1Q2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com